20 (AIDX) EBIT Margin (2025 - 2026)

20 (AIDX) posted EBIT Margin of 408.45% for Q1 2026, down 192.95% on a QoQ basis from 139.43% in Q1 2025, and down 26902.0% year-over-year from N/an in Q1 2025.

20 (AIDX) EBIT Margin (2025 - 2026) Analysis & Trends

20's EBIT Margin history runs 2 years deep, the most recent figure standing at 408.45% for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 12.05%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 15.55%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 19.10%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 21.16%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn 28.97%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 21.42%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn 10.04%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 6.17%
10 20 3.46 Mn -759,563.02 62,884.00 -408.45%

Historic Data

Download Data
DateValue
Mar 31, 2026 -408.45%
Mar 31, 2025 -139.43%